BioNexus Gene Lab (BGLC) EPS (Basic) (2018 - 2026)

BioNexus Gene Lab has disclosed EPS (Basic) across 9 years of filings, most recently posting -$0.22 for Q1 2026.

• EPS (Basic) for Q1 2026 came in at -$0.22, up 35.18% year-over-year; the trailing twelve-month figure through Mar 2026 was -$1.52 (down 150.91% YoY), and the FY2025 annual result was -$1.61, down 79.15% from the prior year.
• EPS (Basic) came in at -$0.22 for Q1 2026 at BioNexus Gene Lab, up from -$0.56 in the prior quarter.
• In the past five years, EPS (Basic) ranged from a high of $0.02 in Q4 2023 to a low of -$0.56 in Q4 2025.
• The 5-year median for EPS (Basic) is -$0.02 (2023), against an average of -$0.14.
• Across the five-year window, EPS (Basic) jumped 709.49% in 2023 and tumbled 5807.26% in 2025, its largest moves.
• BioNexus Gene Lab's EPS (Basic) stood at -$0.0 in 2022, then surged by 709.49% to $0.02 in 2023, then sank by 982.85% to -$0.2 in 2024, then tumbled by 185.47% to -$0.56 in 2025, then surged by 59.7% to -$0.22 in 2026.
• The last three EPS (Basic) figures came in at -$0.22 (Q1 2026), -$0.56 (Q4 2025), and -$0.39 (Q3 2025), per Business Quant data.